Financial PerformanceRevenues increased to £13.9m, ahead of market expectations and up 349% vs. FY23 (£3.1m).
Product DevelopmentFutura's female sexual dysfunction product, WSD4000, has delivered positive results in a home user study, which saw the product deliver an overall positive change in sexual function after four weeks.
Product LaunchThe year saw the business achieve several key milestones including the launch of Eroxon in the US (via partner Haleon) alongside over 15 countries across the Americas, Middle East and Europe.